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Genome-wide association study (GWAS) consortia and collaborations formed to detect genetic
loci for common phenotypes or investigate gene-environment (G*E) interactions are increasingly
common. While these consortia effectively increase sample size, phenotype heterogeneity across
studies represents a major obstacle that limits successful identification of these associations.
Investigators are faced with the challenge of how to harmonize previously collected phenotype
data obtained using different data collection instruments which cover topics in varying degrees of
detail and over diverse time frames. This process has not been described in detail. We describe
here some of the strategies and pitfalls associated with combining phenotype data from varying
studies. Using the Gene Environment Association Studies (GENEVA) multi-site GWAS
consortium as an example, this paper provides an illustration to guide GWAS consortia through
the process of phenotype harmonization and describes key issues that arise when sharing data
across disparate studies. GENEVA is unusual in the diversity of disease endpoints and so the
issues it faces as its participating studies share data will be informative for many collaborations.
Phenotype harmonization requires identifying common phenotypes, determining the feasibility of
cross-study analysis for each, preparing common definitions, and applying appropriate algorithms.
Other issues to be considered include genotyping timeframes, coordination of parallel efforts by
other collaborative groups, analytic approaches, and imputation of genotype data. GENEVA's
harmonization efforts and policy of promoting data sharing and collaboration, not only within
GENEVA but also with outside collaborations, can provide important guidance to ongoing and
new consortia.
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Introduction and overview
The vast majority of genome-wide association studies (GWAS) have focused on the main
effects of gene variants at specific loci on disease outcomes or traits, although most
associations identified so far account for only a small portion of the phenotype variations
seen [McCarthy et al., 2008; Hindorff et al., 2009]. To extend these findings GWAS
consortia and collaborations have formed in which investigators share data to achieve
adequate power to identify genetic loci associated with secondary phenotypes and increase
the power to study less common outcomes [Psaty et al., 2009; Manolio et al., 2007]. There
have been several single center studies of gene-environment (G*E) interactions in complex
disease [Kang et al., 2010; Cornelis et al., 2009] but the development of consortia also offers
the opportunity to enhance power to discover and verify G*E interactions. Investigators
planning new studies and looking to establish consortia or collaborations can share
information on how phenotypes are being measured, what questions are being asked, and
how responses will be coded so that similar data can be combined with relative ease. Tools
such as the PhenX Toolkit of standardized, high priority measures
(https://www.phenxtoolkit.org) are increasingly available to investigators planning new
studies, though most current collaborations involve existing studies whose phenotypes and
data collection instruments are already defined.
While considerable effort has gone into reducing genotype measurement error and ensuring
genotype accuracy and consistency of results [de Bakker et al., 2008], phenotype
heterogeneity, in both outcomes and covariates across studies, represents a major challenge
to successful GWAS analysis of common traits [Zeggini and Ioannidis, 2009; Seminara et
al., 2007] or genome-wide assessment of G*E interactions in complex diseases. The recent
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discovery of markers that are specifically associated with estrogen-receptor negative breast
cancer highlights the potential importance of specific, harmonized phenotypes: earlier
GWAS of a general breast cancer phenotype did not identify these markers, due to lack of
power [Kraft and Haiman, 2010]. In contrast, cross-study analysis groups, such as those
established by the Psychiatric Genetics Consortium [Psychiatric GWAS Consortium
Coordinating Committee et al., 2009], have begun to analyze GWAS results related to
differing psychiatric diagnoses that are known to have shared genetic underpinnings (e.g.
Schizophrenia and Bipolar Disorder, Bipolar and Major Depressive Disorder) [International
Schizophrenia Consortium et al., 2009; Liu et al., 2011]. The existing literature suggests that
phenotype harmonization may reveal novel loci for disease subtypes as well as shared
variants among broad categories of disease. These examples illustrate how phenotype
harmonization is a crucial first step and a key component of successful multi-study
collaboration, where investigators are faced with the challenge of harmonizing previously
collected phenotype data derived from diverse data collection instruments over different
timeframes and in varying degrees of detail.
Phenotype harmonization in GWAS consortia and collaborations involves a multi-stage
process of 1) identifying commonalities and differences in phenotype data to assess the
feasibility and potential benefit of combining data; 2) developing common data definitions
for phenotypes of interest; and 3) creating and applying study-specific algorithms to convert
data into a common format. The goal is to maximize the comparability and compatibility of
data across datasets and to minimize inconsistencies and misclassification [Seminara et al.,
2007]. The process must balance the need to augment the sample size which increases power
for gene discovery with the likelihood of increased data heterogeneity which will decrease
power to detect real effects.
GENEVA (Gene Environment Association Studies) is a multi-site collaborative program
initiated in 2006 as part of the National Institutes of Health (NIH) Genes, Environment and
Health Initiative (GEI) that aims to accelerate the understanding of genetic and
environmental contributions to health and disease [Cornelis et al., 2010]. The GENEVA
consortium, led by the National Human Genome Research Institute (NHGRI) and working
closely with representatives from several institutes at the NIH, includes a Coordinating
Center (CC), two genotyping centers, and fourteen independently-designed GWAS whose
primary outcomes of interest include addiction, blood pressure, cardiovascular disease,
chronic obstructive pulmonary disease, dental caries, type 2 diabetes, lung cancer, maternal
metabolism and birth weight interactions, oral clefts, premature birth, primary open-angle
glaucoma, prostate cancer, stroke, and venous thrombosis. Two additional GWAS
examining coagulation and melanoma joined the consortium in 2009. Each study has
collected relevant environmental exposure data. The participating studies vary widely in
design: some of the longitudinal studies have been ongoing for years or even decades, others
have international data collection sites, and some are family-based studies with phenotype
and genotype data available on multiple family members. Using GENEVA as a practical
example, this paper provides an illustration to guide GWAS consortia through the process of
phenotype harmonization and describes key phenotype harmonization issues that arise when
sharing data across disparate studies. The principles outlined here can also be applied to
other data sharing contexts.
Roles and responsibilities
Phenotype harmonization must be recognized early on as a key requirement for cross-study
collaboration. Key personnel should be identified and, depending on the complexity, size,
number, and primary endpoints of the participating studies, a group or committee should be
established or identified that takes responsibility for directing and overseeing phenotype
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harmonization activities. In GENEVA, three groups are involved in phenotype
harmonization: a Phenotype Harmonization Subcommittee (PHS); the phenotype-specific
Working Groups (WGs); and the Coordinating Center (CC) (Figure 1).
Given the diverse nature of studies supported by GENEVA and their lack of familiarity with
each others' phenotypes, the GENEVA Steering Committing agreed that phenotype
harmonization was a core task warranting investigator participation and leadership, so a PHS
was created. The PHS includes individual study, NIH and CC representatives who are
interested in harmonization of specific phenotypes and exposures or in increasing sample
size for improving power of analyses in their areas of investigation. The Subcommittee
provides a forum for discussion of common problems, sets policies, identifies phenotypes
common across studies, encourages data sharing, establishes and oversees phenotype-
specific WGs, and provides advice, direction and feedback to the CC regarding phenotype
harmonization and related issues.
Phenotype WGs consist of representatives from each study contributing data to that
phenotype's cross-study analyses. These representatives generally have expertise in the
subject area and are aware of the intricacies involved in categorizing or characterizing the
phenotype. The WGs also have representatives from the NIH and the CC. Each WG is led
by an investigator with a specific interest in the phenotype who manages and coordinates the
group's activities. The WGs evaluate the feasibility and logistics for cross-study analyses
related to specific phenotypes of interest. They identify and define variables to be shared,
identify covariates, recommend the most appropriate analytic methods, draft analysis plans
using a template developed by the PHS, and identify the investigators performing the
analyses, usually members of the WG.
The CC is responsible for phenotype data organization and coordinating activities related to
data collection and management and facilitating cross-study analyses. The CC assists the
PHS with identifying potential areas of common interest, harmonizes covariates, and
establishes and manages a centralized relational database which serves as a common
phenotype/genotype repository providing working groups with cross-study data upon
request. The CC assists working groups with phenotype harmonization and provides them
with statistical summaries of phenotype data and a central file-sharing site. The CC may also
assist working group investigators with data analysis, if requested.
Process of Phenotype Harmonization
Phenotype harmonization involves a number of integrated activities (Table 1). Note that the
elements below may be addressed concurrently and not necessarily in the order given.
Identifying common phenotypes
Phenotype harmonization starts with an inventory of phenotypes that investigators are
interested in pursuing during cross-study analyses. For consortia involving only a few
studies, or for consortia in which all studies have a common interest (e.g. stroke), this may
only require a review of data collected by different studies and discussion among
investigators. For collaborations such as GENEVA that incorporate studies of various
designs and diverse outcomes of interest, a more extensive (formal survey) process is
required.
In GENEVA, the CC reviewed the initial phenotype submission plans and data collection
forms for each study. The CC identified overlapping phenotype areas for which data had
been collected, and created a web-based survey (see Supplementary Material, Appendix A)
in which study investigators were asked to indicate, for 13 broad phenotype categories, if (a)
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their study had collected specific data, and if so, (b) the level of sharing, i.e. would they
share it solely with other GENEVA investigators or would they share their data with
authorized researchers through the controlled-access Database of Genotypes and Phenotypes
(dbGaP) [Mailman et al., 2007]. Investigators were invited to list other phenotypes for
which data were available and which could be shared in cross-study analyses. The CC
tabulated responses and provided the information back to the PHS for review and
discussion. If there was interest in a phenotype across three or more studies, the
Subcommittee solicited a volunteer to lead a WG for that phenotype and solicited
nominations for WG members from those studies interested in participating in cross-study
analyses of those phenotypes. If only two studies were able to share data on a specific
phenotype, they could still collaborate and perform cross-study analyses, but a formal WG
might not be required.
Determining feasibility of cross-study analyses
The most important task of the phenotype-specific WGs is to determine the feasibility and
logistics for cross-study analyses related to a given phenotype. The WGs' reviews need to
take into account each study's data scope, consent limitations, and study design, including
the actual questions asked, data collection protocols, phenotype definitions, possible values
or responses, estimated number of individuals for whom there would be phenotype data, and
any other factors that might influence analyses. The primary considerations fall into seven
main categories:
1. Identifying participating studies. An individual study's participation may depend on
how many subjects can participate in the analysis and whether these subjects are
representative of the cohort. This is a complex judgment dependent upon study
size, design, depth and quality of data supporting the phenotype and whether the
primary study outcome is related to the phenotype of interest.
2. Identifying numbers of subjects. It is important to determine whether the number of
subjects resulting from combining studies provides sufficient statistical power to
detect associations between genetic variants and the phenotype of interest. The
estimate of the number of subjects that each study can contribute will help
determine whether the increase in power will be sufficient to justify efforts
associated with harmonization. The combined total number of subjects to be
included in the cross-study analysis also needs to be reassessed and reevaluated
after the following considerations are reviewed.
3. Reviewing consent status. Studies' consent forms define and limit how an
individual's data can be used. The consent limitations for each study contributing
data need to be reviewed by the WG to ensure that the planned analyses are
compatible with the studies' consent limitations. In all instances, the interpretation
of the consent and decision as to which analyses the data can contribute should be
determined by each study's primary investigator in conjunction with the appropriate
Institutional Review Board (IRB), if relevant.
4. Reviewing each study's inclusion/exclusion criteria. Each study's inclusion and
exclusion criteria need to be considered and their impact on any cross-study
analysis evaluated. In some cases appropriate analytic strategies such as sampling
fractions or adjustments may allow participation.
5. Reviewing data definitions. Phenotype and covariate data from different studies
may differ in units of measurement (e.g. kilograms versus pounds), manner of
collection, mode of administration, how questions are worded, and how quantities
or qualities are measured. Each WG needs to decide if the different data sources
and values are compatible and comparable. If they are compatible and comparable,
Bennett et al. Page 5













or can be converted to a common definition (e.g. number of alcoholic drinks per
day to ethanol intake in grams per week), then the WG defines the phenotype
variable for analysis and the possible values.
a. Measured versus self-reported. Data on measured phenotypes (e.g. weight,
blood pressure, serum glucose) will reflect each study's measurement
protocols, laboratory standards, specimen processing, and population
exposures. For example, differences in instrument calibration can
introduce individual-level and study-specific variance. Self-reported
measures such as tobacco use or dietary intake may be more prone to
error, misclassification or misspecification in the questions asked and
possible responses, as well as being more prone to recall bias and varying
degrees of accuracy that reflect subjects' motivation and education, and
questionnaire design, quality and completeness. Such measures may
derive the most benefit from standardization, though hard measures such
as height or glucose levels may also benefit. However, validation of some
self-reported phenotypes such as weight may exist that allow these
phenotypes to be harmonized with directly measured quantitative traits
such as body mass index (BMI) [Rimm et al., 1990].
b. Variations in data definitions. Minor variations in the actual questions
asked by different studies can have significant impact. For instance, in
GENEVA, while some studies asked respondents to report the number of
alcoholic beverages they consumed in a single typical week, others asked
how many drinks they drank in a day, but not how many days they drank
each week.
c. Differences in source populations. The nature of some cohorts can
influence responses such that participants may respond in a manner not
representative of other populations. For example, alcohol consumption
among drug users may be sufficiently different from that of the general
population that the data cannot be compared.
6. Comparing data distributions. Preliminary statistical summaries of the data are
useful for identifying ranges of responses to determine if different studies' data are
comparable and for identifying possible outliers or extreme values. In some
instances, investigators may decide that the data distribution across studies differs
to such an extent that any predictors of the distribution would be unlikely to be the
same and cross-study analyses would be inappropriate. These distributions can also
be used to help investigators define cases and controls for cross-study analyses.
7. Determining if data are being used in similar analyses by other consortia. Large,
well-known longitudinal studies often contribute genotype and phenotype data to
and participate in multiple collaborations and consortia, and this needs to be
considered when the WG plans its analyses. While analyses done within different
collaborations and consortia may share certain characteristics, they may differ in
when data were collected, number of participants and outcomes, technology used to
assess genetic data, number and quality of endpoints, covariate mix, and so on.
Thus, anticipated analyses in one consortium will likely differ from those of
another, and explicit duplication of phenotype and genotype data in analyses should
not be an issue. However, where the planned investigations of the WG and those of
the other consortium overlap, a decision needs to be made regarding the
appropriateness of using the same data in separate but similar analyses. In
GENEVA, one large longitudinal study is part of both GENEVA and another
consortium, and approximately two-thirds of the individuals in GENEVA are
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included in the other consortium's analyses. In this case, the WG and study
representatives decided to exclude from cross-study analyses individuals included
in the other consortium's analyses so that duplication of populations would be
avoided in the analyses performed by the different consortia.
Preparing common definitions
Once the review of the data definitions and values described above indicates that data from
different studies are comparable, common definitions and values need to be agreed upon.
WGs may combine categories into larger units (e.g. drinks per day combined with drinking
days per week to get drinks per week), stipulate inclusion and exclusion criteria (e.g.
excluding those who have never had a drink), create a dichotomous variable (e.g. ever or
never drinker, or use longitudinal and cross-sectional data to define whether the respondent
is a current smoker or has quit smoking), or assign a standard measure to be used (e.g. BMI
calculated from a variety of self-reported or laboratory assessments of height and weight). In
general, the more tightly defined the phenotype, the greater the likelihood that one or more
studies may be unable to contribute to the analyses; the looser the definition, the greater the
likelihood that more subjects and more studies can be included. An example of how data
from various studies might be combined is shown in Tables 2a and 2b.
For continuously distributed outcomes, GENEVA WGs, like other large-scale collaborative
meta-analyses [Lindgren et al., 2009; Thorgeirsson et al., 2010], have applied the same
transformation to all datasets for a single outcome. These transformations are discussed in a
phenotype-specific manner for each meta-analysis and vary across phenotypes. Logical and
extreme outliers are deleted or recoded before transformations are applied to avoid non-
normal error distributions. The removal or recoding of outliers, application of a common
transformation and a strategy for covariate selection (see below) ensures comparability and
interpretation of the estimates from the contributing studies.
Analytic methods
Phenotype WGs determine phenotype definitions, identify covariates, and set inclusion/
exclusion criteria. But they must also consider the advantages and disadvantages of different
analytic approaches, i.e. whether to perform meta-analyses of summary data provided by
each study, analyses of pooled individual-level data, or both. If investigators choose to
perform meta-analyses of summary data, the WG will need to agree on the subgroup
analyses, data format, and analysis method used by each study to produce its summary
statistics. Investigators need to address the following points:
1. Analytic approaches. In consortia such as GENEVA where participating studies
have different designs and participant populations as well as different ethical and
administrative constraints, many investigators prefer to conduct their own analyses
of their study data, generate summary data, and then perform meta-analyses of the
summary statistics. Many study investigators feel that they are best positioned to
control for or otherwise anticipate irregularities in their data that would potentially
be missed in a pooled analysis on one large, combined dataset of individual-level
data conducted centrally. In addition, meta-analyses of summary statistics are much
easier to do than creating and applying study-specific algorithms to convert data
from each study into a harmonized dataset that includes data from all participating
studies. Logistic requirements and ethical concerns (such as sharing individual-
level data) are fewer, and guidelines for meta-analysis of GWAS are available [de
Bakker et al., 2008; Zeggini and Ioannidis, 2009]. However, statistical methods for
G*E interactions are still being developed and non-standard methods requiring
specific statistical programs may be more difficult to conduct across studies using
meta-analysis if expertise is not available for all individual studies. Also, use of
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summary statistics reduces the opportunities for stratification and in-depth analyses
that might be possible by pooling individual level data.
2. Coding disparate variables. If meta-analyses are planned, then each contributing
study's investigators must convert their raw data to conform to the agreed upon
definitions and values before calculating summary statistics. If, instead, an analysis
of pooled, individual-level data is planned, the application of algorithms to convert
individual study data to the common definitions and values can be done by
individual study investigators, and the converted data pooled at a central location,
such as a coordinating center, or the coordinating center may apply the appropriate
algorithm to each study's data.
3. Controlling for admixture. Individual studies should be encouraged to consult with
their analysts for control of admixture during cross-study analyses. In GENEVA it
is now standard practice during the genotype cleaning process to identify genetic
outliers and exclude them from analysis, and include an analysis of population
effects of principal components to further control for admixture.
Selecting and harmonizing covariates
The issues surrounding phenotype harmonization also apply to the selection and
harmonization of covariates. For GENEVA, WGs have identified a standard set of
covariates (e.g. sex and age) applicable to all studies. Other covariates relevant to the
phenotype and that can be easily harmonized across contributing studies (e.g. smoking as a
covariate for caffeine consumption) are also included. Where covariates are relevant to the
characteristics of one study but not to others (e.g. menopause in a sample of older women)
adjustment may be inappropriate and stratified analysis or exclusion may be a more
appropriate strategy. Studies that have divergent assessment protocols for cases and control
subjects have elected, in some instances, to analyze cases and controls separately. This
strategy of uniform covariate selection is similar to that used by several other consortia in
their large-scale meta-analyses [Lindgren et al., 2009; Thorgeirsson et al., 2010] and has led
to comparability of the resulting parameter estimates from individual analyses. However, it
can also result in some study-specific confounds. In GENEVA, it is the responsibility of the
individual study investigators to assess the feasibility and acceptability of covariate
adjustments.
Creating a centralized relational database
Creation of a centralized database and repository for all phenotype and genotype data
provides investigators with the opportunity to easily access the data as they identify new
areas of interest for cross-study analyses. In GENEVA, once each study's genotype and
phenotype data have gone through a standardized quality control cleaning process, the CC
adds each study's phenotype data, data dictionary, individual-level consent and public use or
GENEVA-only use status to a centralized relational database. As the WGs define common
phenotypes and covariates for cross-study analyses, the CC applies study-specific algorithms
to each study's phenotype data to create a dataset and data dictionary for the harmonized
variables and covariates, and these are added to the centralized relational database.
Drafting an analysis plan and performing cross-study analyses
While investigators work through the process of phenotype harmonization, they should
simultaneously develop a preliminary analysis plan as issues will likely arise that affect
harmonization decisions. In GENEVA, each WG drafts a plan for analysis using guidelines
created by the PHS (Table 1), defining the variables or outcomes of interest and their type
(e.g. whether they are discrete, ordinal or continuous variables), identifying covariates
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needed for the analyses, stating inclusion and exclusion criteria (e.g. race or ethnicity, value
limits), describing the planned subgroup analyses and proposed analytic approach, and
specifying individuals' roles in analysis. These plans are refined as preliminary analyses of
the selected phenotypes are conducted by study investigators, and the current plans are
posted on the consortium's website.
For WGs that have decided to conduct meta-analyses of summary data provided by each
study, phenotypes are defined and variables recoded (if necessary) by all studies so that
genome-wide analyses can be done on comparable measures. Analyses of individual study
data are performed by each study's investigators as soon as that study's phenotype and
genotype data have completed the cleaning process. The summary statistics are then
provided to the WG member leading the meta-analysis. Where the WG has decided on an
analysis of pooled individual-level data, the CC applies the appropriate algorithms to each
dataset to harmonize each study's data according to the WG's definition, pools the data into
one combined dataset, and provides this to the investigators doing the analysis.
In general, a majority of meta-analyses of gene effects conducted by GENEVA groups have
adopted a fixed-effects model, with selective testing for random-effects in subsequent
follow-up analyses. Kraft, Zeggini & Ioannidis [Kraft et al., 2009] provide evidence for
reduced power and deflation of the heterogeneity parameter in standard meta-analyses –
hence, heterogeneity testing is restricted to the most promising signals.
Issues related to phenotype harmonization
Genotyping timeframes
Genotyping of the magnitude required for a consortium such as GENEVA, which includes
data on over 80,000 individuals from 16 disparate studies, does not take place on all studies
simultaneously. One study's genotyping results arrive for cleaning and quality control
checks while other studies' samples are being prepared for or are undergoing genotyping.
Therefore genotyping timelines become a critical consideration when planning cross-study
analyses. WGs must consider that GWAS results are emerging in the context of sharp
competition among various research groups for publication, and there should be an ongoing
process to decide when sufficient numbers are available to conduct a study that represents a
meaningful advance. WGs may decide to proceed with data analyses when only a few
studies are complete and if statistical thresholds are achieved because discoveries relating to
the phenotype of interest are emerging so rapidly. The data from studies whose genotype
results will be completed later can be used for replication analyses. Alternate strategies
might be to wait until more studies' genotype results are available, refine the phenotype
definitions so the group can conduct more specific, stratified analyses of key phenotypes, or
collaborate with outside consortia doing similar investigations.
Working with external collaborative groups
There are a large number of consortia undertaking GWAS analyses (Table 3) and the
phenotypes under investigation by various consortia often overlap. Negotiations with other
consortia WGs can lead to collaborations where GWAS investigators can contribute to data
analyses being led by other consortia. This benefits both groups—investigators are able to
contribute to primary analyses of an important phenotype and the collaboration's primary
analyses now include data on additional individuals. Studies that are still being genotyped
can contribute to later analyses. Alternatively, investigators may decide to serve as a
replication study or look at other related or intermediate phenotypes or associations and G*E
analyses beyond the initial ones being conducted. There are, of course, implications of
overlapping data across independent meta-analyses and in some instances, such overlap is
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unavoidable. In those instances, appropriate corrections, such as those described by Lin &
Sullivan [Lin DY and Sullivan PF, 2009], might be considered.
The sample size-phenotype heterogeneity paradox
Inevitably an increase in sample size achieved by pooling samples across studies introduces
phenotype heterogeneity that may alter the power to discover genes or G*E interactions for
a complex trait of interest. During gene discovery, the balance between power achieved by
larger sample size versus loss of power produced by introduced phenotype heterogeneity
during phenotype harmonization may favor the former. For example, little is known about
the genetic architecture of primary open-angle glaucoma (POAG) although the sib relative
risk is 10 [Wolfs et al., 1998]. Icelandic investigators reported two SNPs between CAV1 and
CAV2 associated with POAG with an OR of ∼1.3 and with a p-value of 5E-10 [Thorleifsson
et al., 2010]. Several replication datasets were provided and phenotype definitions varied
widely. Not all replication sets achieved statistical significance and several had wide
confidence intervals. When the replication sets were combined they did achieve significance
with an effect size and confidence comparable to that reported in the discovery set. This
suggests that the association between CAV1 and CAV2 gene variants and POAG represents
a true positive and that pooling samples during the phenotype harmonization process can
provide power even in the face of phenotype heterogeneity during gene discovery, although
this might not be generalizeable to all complex traits.
On the other hand, when trying to identify G*E interactions for a phenotype with known
genetic architecture, the balance between power gained by adding more samples versus
power degradation produced by phenotype heterogeneity may favor the latter. The tradeoff
between sample size and phenotypic heterogeneity of exposure data is modeled in Figure 2
[Lindstrom et al., 2009]. This hypothetical example considers a rare disease (prevalence 1 in
1,000), no main effect for the binary genetic factor (with 20% prevalence), an odds ratio of
1.5 for the exposure, an interaction odds ratio of 1.35, and a Type I error rate of 5E-8. This
illustrates the power of a case-control study to detect a G*E interaction (departure from a
multiplicative odds model) when the binary exposure is measured perfectly or via a good
proxy with 77% specificity and 99% sensitivity (roughly analogous to self-reported versus
measured overweight status). Figure 2 illustrates that even modest misclassification can
greatly decrease the power of tests for G*E interaction (and the relative decrease is greater
for rare exposures). On the other hand Figure 2 also illustrates that a large study using the
proxy can have greater power than a smaller study using the perfect measure, although the
power gain is modest at best. Nevertheless, the modest power gain may be important when
the perfect measure is prohibitively expensive or only available on a small fraction of
samples, while the good measure is relatively inexpensive or already available on many
samples.
Genotype imputation
In many consortia or collaborations, different studies' samples may be genotyped on
different platforms or may be genotyped using different versions of the same technology.
This is particularly true when large studies are conducted over time because the technology
is continuously evolving. Imputation tries to address these differences [Li et al., 2009], but
this, too, can create more uncertainties in data comparability when investigators use
different software packages to impute data. In GENEVA, genotyping is being performed on
both Affymetrix and Illumina platforms with varying degrees of single nucleotide
polymorphism (SNP) coverage. In addition, the two platforms detect different sets of SNPs.
Plans to conduct imputation vary widely across studies, and there has been considerable
discussion regarding the comparability of imputation results performed at different sites
using different HapMap reference panels [http://hapmap.ncbi.nlm.nih.gov] and software
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packages (MACH [http://www.sph.umich.edu/csg/abecasis/MACH/index.html; Li et al.,
2009; Li et al., 2006], Impute [https://mathgen.stats.ox.ac.uk/impute/impute.html; Marchini
et al., 2007; Howie et al., 2009] and BEAGLE
[https:faculty.washington.edu/browning/beagle/beagle.html; Browning and Browning, 2009]
being the most common). Most WGs are utilizing individual investigators' imputation results
and reviewing preliminary analyses of individual study data to ensure that analyses yield
similar findings. Another solution for consortia, and one adopted by GENEVA, is to have all
genotype data imputed centrally using a standard methodology.
Converging on an analytic framework
As previously mentioned, pivotal issues WGs face when combining or harmonizing data
from different studies are determining the analytic plan and the precise modeling strategy,
adjusting for confounders, and performing stratified analysis. WGs continually consider, for
instance: (a) whether waves of longitudinal data should be combined for comparability to
cross-sectional studies; (b) whether analyses should be adjusted for covariates, such as
ethnicity, or conducted separately in each group; (c) whether analyses should remove,
truncate, or adjust for outliers (e.g. by normalizing distributions) and how these outliers are
defined; (d) which statistical models accommodate the nuances of each dataset; and (e)
whether studies should focus on main effects of individual SNPs, candidate genes, on gene
systems or on gene-by-gene (G*G) and G*E analyses. Overarching these phenotype issues
are comparable concerns regarding uniform quality control metrics for genotype data and
comparable imputation statistics which add inherent complexity to the process. A pre-
determined analytic strategy for the main gene discovery stage as well as approaches to G*E
and G*G associations requires special planning as there is no standard approach though all
agree that very large numbers are required to support the enhanced power requirements of
G*E investigations [Garcia-Closas and Lubin, 1999; Kraft and Hunter, 2005].
Phenotype harmonization when using controls for cases
Many investigators are now looking at using controls from one study as cases in another
study as a way of expanding the size of an investigation without the cost of genotyping
additional individuals. However, it is only possible when the subjects come from studies
whose primary interests are not associated with each other. This becomes complex because
it requires well-characterized phenotypes for selection of cases and controls, yet many of the
phenotypes are secondary measures collected by the contributing studies and thus may not
be well-characterized. Such phenotypes also may represent only a snapshot of the
individual's phenotype at one point in time and may not be correlated with the development
of future disease or conditions. GENEVA currently has a WG looking specifically at this
issue, and its investigation is still in progress.
Progress
The infrastructure and processes described here have enabled GENEVA investigators to
address common problems, facilitated the generation of new ideas for research and cross-
study analyses, and provided GENEVA investigators with a means of turning these
questions into active areas of study. GENEVA initially convened seven phenotype WGs.
These included anthropometry, alcohol use, smoking, caffeine use, female reproductive
history, psychiatric history, and oral health. As groups met and discussed the details of how
and what data were collected, a few collaborations were determined to be not feasible (e.g.
psychiatric history was not adequately addressed across most of the studies) and one group
found that the distribution of data between two studies differed to such an extent that cross-
study analyses were inappropriate. However, as investigators have become familiar with the
various studies and with each other, and as new studies have joined the consortium, several
Bennett et al. Page 11













new areas of mutual interest (e.g. sleep, protective effects, and physical activity) were
identified and prompted the formation of new WGs. Each WG has identified one or more
key phenotypes for which three or more studies are contributing data (Table 4). Thus far,
eleven studies have genotype and phenotype data that have undergone consortium-level
quality control and assurance. Six studies have so far contributed data to cross-study
analyses, and an additional six have plans to contribute data to cross-study analyses.
Summary
Large consortia have emerged to correlate phenotypes with specific variants at certain
genetic loci but the strategies and pitfalls associated with combining phenotype data from
varying studies have not previously been described in detail. A key recent critique of GWAS
reveals a principal concern with effect sizes [Goldstein, 2009] suggesting that meta-analyses
of complex traits may be the avenue to successful gene discovery. Consortia-based studies
that incorporate the approaches described here will be essential to achieving the power to
support investigations of effect sizes demonstrated to be typical [Garcia-Closas and Lubin,
1999].
GENEVA is unusual in the diversity of its studies, yet the issues it has had to face in sharing
data are common to all collaborations. GENEVA's harmonization efforts have important
applications to current consortia that struggle with study heterogeneity but that seek to
maximize the use and value of their data or extend their current data to explore the genetic
architecture of novel but relevant traits.
Furthermore, GENEVA's policy to promote data sharing and collaboration, not only within
GENEVA but also with other consortia and collaborations outside of GENEVA, has
presented unique challenges in harmonization. Our experience demonstrates that systematic
planning by a knowledgeable Coordinating Center, a team of collaborative investigators, and
engaged program staff from the funding agency, are critical for maximizing the scientific
return from large-scale GWAS. Collaborations such as GENEVA can stimulate
development of novel methodologies for phenotype harmonization which, hopefully, will
actively translate into steps towards identification of genetic loci important for traits related
to health and disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Phenotype harmonization roles and responsibilities in GENEVA
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Power of a case-control study to detect a gene-environment interaction (departure from a
multiplicative odds model) when the binary exposure is measured perfectly or via a good
proxy with 77% specificity and 99% sensitivity (roughly analogous to self-reported versus
measured overweight status)
This figure illustrates several points: a) large samples sizes are needed to detect gene-
environment interactions; b) even modest misclassification can greatly decrease the power
of tests for gene-environment interaction (and the relative decrease is greater for rare
exposures); yet c) a large study using the proxy can have greater power than a smaller study
using the perfect measure. This last point is important when the perfect measure is
prohibitively expensive or only available on a small fraction of samples, while the good
measure is relatively inexpensive or already available on many samples. Power calculations
were performed using the methods described in Lindstrom et al. (2009), assuming a rare
disease (prevalence 1 in 1,000), no main effect for the binary genetic factor (with 20%
prevalence), an odds ratio of 1.5 for the exposure, an interaction odds ratio of 1.35, and a
Type I error rate of 5×10-8.
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Table 1
Phenotype harmonization and analysis plan check list
Items may be addressed concurrently and not necessarily in this order.
Establish a group and group leader
• Identify a leader interested and willing to drive the process forward
• Include representatives from all studies and groups contributing data and any other groups (such as a coordinating center)
contributing to the work
Identify common phenotypes of interest (including covariates)
• Review available data—what was collected and what can be shared
– Review data collection forms and questionnaires
– Create a spreadsheet of phenotypes showing which studies collect which variables
– Create a web-based or other survey, if appropriate
Determine feasibility of cross-study analyses
• Identify participating studies
– Are the subjects representative of the cohort
• Identify approximate numbers of subjects to be included in cross-study analyses
– Is the combined total number of subjects sufficient to detect a significant association
• Review consent status of each contributing study
– Do planned analyses fall within the scope of the data use statements of the consent forms used by each study
• Review each study's inclusion and exclusion criteria
– Are there studies for which the inclusion/exclusion criteria make their inclusion in the cross-study analysis not useful
• Review data definitions from each contributing study
– What exactly was asked (or measured)—compare the wording of the actual questions
– Are response options comparable
• Compare data distributions
– If data distributions are not similar, i.e. if there is little overlap, the data may not be comparable
• Confirm that the data are not being used for similar analyses by another collaboration or consortium
Prepare common definitions
• Prepare phenotype definition
– Define the outcome of interest and values
– Define the outcome type—whether discrete, ordinal, continuous
Code variables
• Create algorithms for converting each study's raw data to conform to the agreed upon definitions
Draft an analysis plan
• Describe the phenotype, covariates, and inclusion/exclusion criteria
• List participating studies and anticipated number of subjects contributing to the analyses
• Describe the planned subgroup analyses
• Describe the analysis approach
– How will outliers be handled
♦ Will outliers be Windsorized (i.e. equated to the next highest/lowest value)
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♦ Will extreme values be truncated (e.g. to 4 standard deviations of sample mean)
– How will missing values be handled
– How will covariates be adjusted for
– How will data from longitudinal studies (studies with data from multiple time points) be combined with data from
cross-sectional studies
♦ Will a date range be chosen for which data values to include
– Determine which statistical model fits best; often several models are needed
– Identify type of analysis, i.e. meta-analyses of summary statistics or analyses of pooled individual data
– Describe the statistical support required and who will provide it
– Describe the imputation plan
♦ Who will be responsible for imputation, i.e. will this be done by individual studies or will it be done
centrally
– Identify any candidate genes that can be examined
– Identify key personnel and their roles
♦ Who at each site and/or the CC will be doing analyses
♦ Who will be the primary author
♦ Will any assistance be required from the CC
♦ What will be the role of the CC
– Develop a timeline—genotype and phenotype data for different studies may not be ready at the same time
♦ When can analyses start and what studies will be included
♦ How will studies whose data will be ready later be incorporated into the analysis
– Relationship to work being done in other consortia/collaborations
♦ How do these analyses fit in with what other consortia are doing
♦ Can collaborations be established with another consortium to combine data for a primary analysis
♦ Can the other consortium's data serve as a replication study
♦ What specific associations and G*E analyses can be performed that have not been already examined
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Table 2
Table 2a. Examples of possible smoking-related questions
Study
(N)
Smoking-related questions Possible responses
Study 1
(2,500)
1. Do you currently smoke cigarettes? Y/N
2. If yes, how many cigarettes per day? ###
Study 2
(1,200)
1. Have you smoked more than 100 cigarettes in your lifetime? Y/N
2. If yes, do you currently smoke? Y/N
3. If yes, how many packs per day do you smoke? ##
Study 3
(8,500)
1. Have you ever smoked? Y/N
Study 4
(1,250)
1. Do you currently smoke? Y/N
Study 5
(4,200)
1. Do you smoke? Y/N
2. When did you first start smoking regularly? Past year; 1-5 years ago; >5 years ago
Study 6
(6,600)
1. Have you smoked tobacco in the past month? Y/N
Study 7
(800)
1. Have you ever smoked regularly? Y/N
2. If yes, do you still smoke? Y/N
3. If yes, how much do you smoke a day? 1-10 cigarettes, 11-20 cigarettes, 21-30 cigarettes, >30 cigarettes
Table 2b. Examples of possible new variables for cross-study analyses
New variable Studies that could contribute data Total
N
Comment
Cigarettes per day Study 1 2,500 Data from Study 7 might also be included if specific
values were assigned to each response category, e.g. 5
for category ‘1-10 cigarettes’, 15 for category ‘11-20
cigarettes’, and so on
Packs per day Study 1 (if convert cigarettes/day to packs/day) 4,500
Study 2
Study 7 (if convert categories to packs/day)
Former smoker Study 2 2,000
Study 7




Current smoker Study 1 16,550
Study 2
Study 4
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Table 2b. Examples of possible new variables for cross-study analyses




Study 6 (if current smoker is defined as having
smoked in the past month)
Study 7
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